Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE)
ClinicalTrials.gov Identifier: NCT02798406
UCLA IRB #: 16-000576
Sponsor: Arbor Pharmaceuticals, Inc.
Time Frame: 3.5 years
Purpose: Glioblastoma (GBM) and gliosarcoma (GS) are the most common and aggressive forms of malignant brain tumor in adults and can be resistant to conventional therapies. The purpose of this Phase II study is to evaluate how well a recurrent glioblastoma or gliosarcoma tumor responds to one injection of DNX-2401, a genetically modified oncolytic adenovirus, when delivered directly into the tumor followed by the administration of intravenous pembrolizumab (an immune checkpoint inhibitor) given every 3 weeks for up to 2 years or until disease progression.
Principal Investigator: Timothy Cloughesy, MD